Antitumor Peptide-Based Vaccine in the Limelight

The success of the immune checkpoint blockade has provided a proof of concept that immune cells are capable of attacking tumors in the clinic. However, clinical benefit is only observed in less than 20% of the patients due to the non-specific activation of immune cells by the immune checkpoint block...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumai, Takumi, Yamaki, Hidekiyo, Kono, Michihisa, Hayashi, Ryusuke, Wakisaka, Risa, Komatsuda, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778374/
https://www.ncbi.nlm.nih.gov/pubmed/35062731
http://dx.doi.org/10.3390/vaccines10010070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778374/
https://www.ncbi.nlm.nih.gov/pubmed/35062731
http://dx.doi.org/10.3390/vaccines10010070

Ejemplares similares